HUP0401665A1 - Egy aminotiazolil-acetanilid-származék alfa- és béta-kristályalakja, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Egy aminotiazolil-acetanilid-származék alfa- és béta-kristályalakja, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0401665A1
HUP0401665A1 HU0401665A HUP0401665A HUP0401665A1 HU P0401665 A1 HUP0401665 A1 HU P0401665A1 HU 0401665 A HU0401665 A HU 0401665A HU P0401665 A HUP0401665 A HU P0401665A HU P0401665 A1 HUP0401665 A1 HU P0401665A1
Authority
HU
Hungary
Prior art keywords
aminothiazolyl
alfa
beta
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0401665A
Other languages
English (en)
Inventor
Souichirou Kawazoe
Kenichirou Sakamoto
Yuji Awamura
Tatsuya Maruyama
Takayuki Suzuki
Kenichi Onda
Toshiyuki Takasu
Original Assignee
Yamanouchi Pharmaceutical Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19148268&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0401665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co. Ltd. filed Critical Yamanouchi Pharmaceutical Co. Ltd.
Publication of HUP0401665A1 publication Critical patent/HUP0401665A1/hu
Publication of HUP0401665A3 publication Critical patent/HUP0401665A3/hu
Publication of HU230481B1 publication Critical patent/HU230481B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

%-5> A találmány tárgyát képezi az (R)-2-(2-amino-tiazol-4-il)-4'-[2-[(2-hidroxi-2-fenil-etil)-amino]-etil]-acetanilid a- és b-kristályalakja, és hatóanyagként való alkalmazásuk diabétesz ellenigyógyszer előállítására. Az a-kristályalak nem mutat higroszkóposságotés stabil, így alkalmazható gyógyszerként és felhasználható az iparitermelés tömegszintézisére. A b-kristályalak viszonylag kishigroszkóposságot mutat és szintén felhasználható az a-kristályalakelőállítási intermediereként. Ó
HU0401665A 2001-10-30 2002-10-29 Egy acetanilid-származék alfa kristályalakja HU230481B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-332914 2001-10-30
JP2001332914 2001-10-30
PCT/JP2002/011217 WO2003037881A1 (fr) 2001-10-30 2002-10-29 Cristal a forme $g(a) ou $g(b) d'un derive acetanilinide

Publications (3)

Publication Number Publication Date
HUP0401665A1 true HUP0401665A1 (hu) 2004-11-29
HUP0401665A3 HUP0401665A3 (en) 2008-05-28
HU230481B1 HU230481B1 (hu) 2016-07-28

Family

ID=19148268

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401665A HU230481B1 (hu) 2001-10-30 2002-10-29 Egy acetanilid-származék alfa kristályalakja

Country Status (17)

Country Link
US (2) US7342117B2 (hu)
EP (3) EP1932838A3 (hu)
JP (1) JP3800220B2 (hu)
KR (1) KR100908796B1 (hu)
CN (1) CN1243740C (hu)
AU (1) AU2002344419C1 (hu)
BR (1) BRPI0213570B8 (hu)
CA (1) CA2464068C (hu)
ES (1) ES2404071T3 (hu)
HU (1) HU230481B1 (hu)
MX (1) MXPA04003936A (hu)
NO (1) NO326965B1 (hu)
PL (1) PL218982B1 (hu)
RU (1) RU2303033C2 (hu)
TW (1) TW200300020A (hu)
WO (1) WO2003037881A1 (hu)
ZA (1) ZA200403044B (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
MXPA05004925A (es) * 2002-11-07 2005-08-18 Yamanouchi Pharma Co Ltd Remedio para vejiga hiperactiva que incluye derivado de anilida de acido acetico como el ingrediente activo.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009057685A1 (ja) * 2007-11-02 2009-05-07 Astellas Pharma Inc. 過活動膀胱治療用医薬組成物
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
WO2010147830A2 (en) * 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20120070465A1 (en) 2010-03-29 2012-03-22 Astellas Pharma Inc. Pharmaceutical composition for modified release
EP2583967B1 (en) * 2010-06-16 2014-10-01 Takeda Pharmaceutical Company Limited Crystal of amide compound
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
IN2013CN09704A (hu) * 2011-05-18 2015-07-03 Reddys Lab Ltd Dr
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
WO2013147134A1 (ja) 2012-03-30 2013-10-03 アステラス製薬株式会社 ミラベグロン含有医薬組成物
CN103387500A (zh) * 2012-05-11 2013-11-13 上海医药工业研究院 一种米拉贝隆及其中间体的制备方法
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2891493A4 (en) 2012-08-31 2016-05-18 Astellas Pharma Inc MEDICAL COMPOSITION ADMINISTERED ORALLY
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme BICYCLIC ANTIDIABETIC COMPOUNDS
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (it) 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103641792B (zh) * 2013-12-27 2015-07-22 国药集团国瑞药业有限公司 一种米拉贝隆有关物质或其盐、其制备方法和用途
CN104876889B (zh) * 2014-02-27 2017-02-22 人福医药集团股份公司 化合物的合成方法
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
CN103896872A (zh) * 2014-04-29 2014-07-02 黑龙江大学 米拉贝隆的合成方法
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
EP3177589B1 (en) 2014-08-06 2018-06-20 Interquim, S.A. Method for the synthesis of mirabegron and its derivatives
WO2016024284A2 (en) 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN105481705A (zh) * 2014-08-23 2016-04-13 南京海纳医药科技有限公司 (r)-2-[[2-(4-氨基苯基)乙基]氨基]-1-苯乙醇的制备及应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
US10149837B2 (en) 2014-09-26 2018-12-11 Universita' Degli Studi Di Bari Selective agonists of beta-adrenergic type 3 receptors (BAR3) and use thereof
US20170291882A1 (en) * 2014-10-01 2017-10-12 Apotex Inc. Solid Forms of Mirabegron
JP2018508497A (ja) 2015-02-02 2018-03-29 ルピン・リミテッド ミラベグロンの多形型の調製方法
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
FR3043555B1 (fr) * 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) Mirabegron pour le traitement de maladies retiniennes
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
CN105801438A (zh) * 2016-04-12 2016-07-27 济南大学 一种米拉贝隆中间体的合成方法
CN107963976A (zh) * 2016-10-20 2018-04-27 中国动物疫病预防控制中心 一种苯乙醇胺类化合物中间体的制备方法
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3360866B1 (en) 2017-02-14 2019-01-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
CN108658797A (zh) * 2018-06-19 2018-10-16 安徽德信佳生物医药有限公司 一种米拉贝隆中间体(r)-2-(4-硝基苯乙基氨基)-1-苯基乙醇盐酸盐的合成
CN108947853A (zh) * 2018-06-29 2018-12-07 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成米拉贝隆中间体的方法
KR101928987B1 (ko) * 2018-08-28 2018-12-13 (주) 성운파마코피아 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
CN110590699B (zh) * 2019-09-29 2022-11-15 广东先强药业有限公司 一种米拉贝隆的精制方法
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
CN114539182A (zh) * 2020-11-24 2022-05-27 威智医药有限公司 转晶溶剂及其应用和米拉贝隆α晶型的制备方法
CN114539084B (zh) * 2020-11-24 2024-04-02 威智医药股份有限公司 米拉贝隆及其中间体的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
CN112574137A (zh) * 2021-01-19 2021-03-30 南京美瑞制药有限公司 一种α晶型米拉贝隆的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1921577B2 (de) * 1969-04-28 1972-04-06 Nixdorf Computer Ag, 4790 Paderborn Trommelartige vorrichtung zn buchungs- und schreibautomaten mit greifeinrichtung zum erfassen und einziehen von kontokarten o dgl
JPH02279685A (ja) 1989-04-18 1990-11-15 Yoshitomi Pharmaceut Ind Ltd 新規な結晶構造を有するチアジアジン化合物およびその製造法
EP1028111B1 (en) * 1997-10-17 2004-05-12 Yamanouchi Pharmaceutical Co. Ltd. Amide derivatives or salts thereof
JP3901832B2 (ja) 1998-03-13 2007-04-04 大日本インキ化学工業株式会社 キノリノン誘導体製剤、及びその製造法
JP2000212168A (ja) 1999-01-22 2000-08-02 Yamanouchi Pharmaceut Co Ltd ヘキサヒドロ―１，４―ジアゼピン誘導体塩水和物の新規結晶
EP1129712A4 (en) * 1999-09-10 2002-11-05 Dainippon Ink & Chemicals PREPARATIONS OF QUINOLINONE DERIVATIVES AND THEIR PRODUCTION METHOD
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative

Also Published As

Publication number Publication date
BRPI0213570B8 (pt) 2021-05-25
RU2303033C2 (ru) 2007-07-20
JP3800220B2 (ja) 2006-07-26
HUP0401665A3 (en) 2008-05-28
AU2002344419B2 (en) 2007-12-13
KR100908796B1 (ko) 2009-07-22
EP2298752B1 (en) 2013-03-27
PL369874A1 (en) 2005-05-02
EP1932838A2 (en) 2008-06-18
US20050004190A1 (en) 2005-01-06
NO326965B1 (no) 2009-03-23
WO2003037881A1 (fr) 2003-05-08
US7342117B2 (en) 2008-03-11
ES2404071T3 (es) 2013-05-23
US20080214633A1 (en) 2008-09-04
EP2298752A1 (en) 2011-03-23
JPWO2003037881A1 (ja) 2005-02-17
TW200300020A (en) 2003-05-01
KR20050040837A (ko) 2005-05-03
CA2464068C (en) 2007-10-16
EP1932838A3 (en) 2008-07-30
TWI322805B (hu) 2010-04-01
ZA200403044B (en) 2005-06-29
RU2004116313A (ru) 2005-03-27
CN1575287A (zh) 2005-02-02
EP1440969A1 (en) 2004-07-28
CN1243740C (zh) 2006-03-01
BRPI0213570B1 (pt) 2018-02-27
EP1440969A4 (en) 2005-01-19
NO20042227L (no) 2004-05-28
US7982049B2 (en) 2011-07-19
HU230481B1 (hu) 2016-07-28
BR0213570A (pt) 2004-10-26
PL218982B1 (pl) 2015-02-27
AU2002344419C1 (en) 2024-02-01
MXPA04003936A (es) 2004-06-18
CA2464068A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
HUP0401665A1 (hu) Egy aminotiazolil-acetanilid-származék alfa- és béta-kristályalakja, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0400240A2 (hu) Szubsztituált oxazolidinonszármazékok és más hatóanyagok kombinációi és ezeket tartalmazó gyógyszerkészítmények
BR0307060A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
ES2133504T3 (es) Derivados peptidicos del acido boronico con una actividad inhibidora de proteasa, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CY1107703T1 (el) Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης
DK0766696T3 (da) Thiazolidinderivater, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser
NO995963L (no) Karboksamider anvendelige som 5-HTIF-agonister
HUP0401504A2 (hu) Antidiabetikumként és kóros elhízás elleni szerekként alkalmazható szubsztituált azol-karbonsavszármazékok és az ezeket tartalmazó gyógyszerkészítmények
SE0101038D0 (sv) Novel compounds
HUP0401092A2 (hu) 6-Fenil-7-[(fluor-alkil)-amino]-5-halogén-triazolopirimidinek mint fungicidek, előállításuk és alkalmazásuk
HUP0104033A2 (hu) Benzoilpiridazin-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk
HUP0203884A2 (hu) Kristályos oximinoalkánsav-származékok és cukorbaj elleni alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
IT1300055B1 (it) Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici
HUP0401318A2 (hu) 2,3,4,5-Tetrahidro-benzo[b] tiepin-1,1-dioxid-származékokat és további hatóanyagokat tartalmazó kombinációs készítmények és ezek alkalmazása
CY1109545T1 (el) Συνθεση της (r) και (s)-αμινοκαρνιτινης και παραγωγων που προκυπτουν απο to d- και l- ασπαρτικο οξυ
WO2001060822A8 (fr) Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece
HUP0300651A2 (hu) Nátrium-hidrogén-cserélő 1-es típusú inhibitor (NHE-1) alkalmazása gyógyszerkészítmények előállítására és ezt tartalmazó gyógyszerkészítmények
PE9296A1 (es) Forma polimorfica cristalina de (s,s,s)- n- (1-[ 2- carboxi- 3-(n�- mesil- lisilamino) propil]- 1-ciclopentil carbonil )tirosina (forma o) y procesos de obtencion
HUP0303174A2 (hu) A terbinafin almasav addíciós sói, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0003710A2 (hu) 2-[3-{4-[2-terc-Butil-6-(trifluor-metil)-4-pirimidinil]-1-piperazinil}-propil-tio]-4-pirimidinol-fumarát, valamint ezt a vegyületet tartalmazó gyógyászati készítmény
ATE298564T1 (de) Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
IT1300056B1 (it) Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
HUP0301199A2 (hu) Dioxo-tiazolidin-származék és antidiabetikumként történő alkalmazása
UA48057A1 (uk) 5-АЛКІЛ-2-(1,3,4-ТІАДІАЗОЛІЛ)АМІДИ-<font face="Symbol">a</font>-МЕТИЛ-<font face="Symbol">d</font>-ДІЕТИЛАМІНОБУТИЛАМІДУ БУРШТИНОВОЇ КИСЛОТИ, ЯКІ МАЮТЬ ПРОТИЗАПАЛЬНУ АКТИВНІСТЬ